Various guidelines for hypertension specify that the target blood pressure (BP) should be below 140/90 mm Hg and that strict control is recommended for patients with cardiovascular risk factors. We examined the relationship between the achieved BP and the incidence of cardiovascular events in hypertensive patients with complications as a sub-analysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. A total of 4703 patients were evaluated for efficacy in the CASE-J trial. In this sub-analysis, 4553 patients had at least one follow-up visit without any cardiovascular events. We examined the relationship between the achieved BP and cardiovascular events in hypertensive patients with type II diabetes mellitus (DM), chronic kidney disease (CKD) or left ventricular hypertrophy (LVH) at baseline. Possible baseline confounders were adjusted by using the multiple Cox regression model. A higher achieved BP was associated with an increased risk of cardiovascular events in hypertensive patients with complications (DM, CKD or LVH). In patients with LVH, who achieved systolic/diastolic BP (SBP/DBP) o130/75-79 mm Hg, the risk of cardiovascular events was reduced to the same level of SBP/DBP o130/75-79 mm Hg in those without LVH. However, the risks of cardiovascular events in patients with DM or CKD, who achieved SBP/DBP o130/75-79 mm Hg, were still significantly higher than in those without DM or CKD. In conclusion, this study extended the significance of BP control in hypertensive patients especially with complications. Further investigation in a large-scale clinical trial is needed to determine the optimal target BP for LVH patients.
INTRODUCTION
The prognosis of patients with hypertension does not only depend on the blood pressure (BP) but also on other cardiovascular risk factors (smoking, diabetes, advanced age and family history) and comorbidities, such as hypertensive organ damage and cardiovascular disease. In particular, hypertensive patients with diabetes mellitus (DM) have been reported to have a high risk of suffering from cardiovascular events, 1-3 and aggressive antihypertensive therapy is recommended for such patients in several guidelines. [4] [5] [6] Control of hypertension is also required to prevent the progression of renal impairment. 7 Thus, strict BP control is essential for hypertensive patients with DM and/or chronic kidney disease (CKD). Cardiac hypertrophy is often associated with other cardiovascular diseases, such as hypertension and ischemic heart disease, and is one of the independent risk factors that influence the prognosis of hypertensive patients. Owing to cardiac events and heart failure, both mortality and morbidity are increased in hypertensive patients with left ventricular hypertrophy (LVH). 8 We recently performed the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J trial), which was a large-scale clinical trial in high-risk hypertensive patients that compared an angiotensin II receptor blocker (candesartan cilexetil) and a calcium channel blocker (amlodipine besylate) with respect to the prevention of cardiovascular events. 9 The incidence of cardiovascular events in the CASE-J trial occurred relatively lower compared with previous similar studies, such as the Valsartan Antihypertensive Long-term Use Evaluation trial, 10 and the CASE-J trial showed no significant difference between the candesartan and amlodipine groups. 11 The achieved BP in the CASE-J trial was lower than that in large-scale clinical trials reported earlier, suggesting that the strict BP control overcame the differences of pharmacological action between the two antihypertensive agents.
The CASE-J trial provides us with the opportunity to verify the significance of BP control in high-risk hypertensive patients. In this study, we performed a sub-analysis of the CASE-J trial to examine the relationship between the achieved BP and the incidence of cardiovascular events in patients with DM, CKD or LVH.
METHODS

Study population and treatment
The original CASE-J trial was a prospective randomized open-label blinded-end point study. Details of the study protocol and the main results have been reported earlier. 9, 11 The subjects of the CASE-J trial were high-risk patients with essential hypertension, who had at least one of the following cardiovascular risk factors: (1) sitting systolic BP (SBP) X180 mm Hg or diastolic BP (DBP) X110 mm Hg; (2) type II DM; (3) a history of stroke or transient ischemic attacks; (4) LVH, angina pectoris or a history of myocardial infarction; (5) proteinuria or renal dysfunction (serum creatinine 41.3 mg per 100 ml); or (6) peripheral arterial disease (Fontaine classification grade II or higher). After randomization, the enrolled patients were given one of the two following medications to achieve the targets for control of BP according to the guidelines developed by the Japanese Society of Hypertension (JSH): 12 o60 years old, SBP/DBP o130/85 mm Hg; 60s, SBP/DBP o140/90 mm Hg; 70s, SBP/DBP o150/90 mm Hg; and 80s, SBP/DBP o160/90 mm Hg. The one of the medication given was candesartan administered orally at a dose of 4-8 mg day À1 . When the BP did not reach the targets for the control of BP, the dose was increased up to 12 mg day À1 . The other medication was amlodipine administered orally at a dose of 2.5-5 mg day À1 and increased up to 10 mg day À1 when necessary. Once a patient was given the assigned medication, the use of other angiotensin II receptor blockers, calcium channel blockers and all angiotensinconverting enzyme inhibitors was prohibited. Patients already being treated with diuretics, a-blockers, b-blockers or a-and b-blockers before enrollment were allowed to continue taking these medications.
End point and event evaluation criteria
The primary outcome for this sub-analysis was defined as any of the following cardiovascular events (whichever occurred first): sudden death; stroke/transient ischemic attack; acute myocardial infarction, heart failure or angina pectoris; doubling of serum creatinine or an increase to X4.0 mg per 100 ml or endstage renal disease; dissecting aortic aneurysm; and occlusive peripheral arterial disease.
Occurrence of each event was independently judged by an independent event evaluation committee. The summary of the definition was as follows:
(1) sudden death-unexpected abrupt death within 24 h without external cause; (2) cerebrovascular event-new onset or recurrence of stroke, transient ischemic attack (local neurological symptoms completely resolve within 24 h and symptoms develop rapidly) and other cases of stroke that are not classifiable; (3) cardiac event-new onset or recurrence of acute myocardial infarction according to the diagnostic criteria of World Health Organization (WHO)/Monica Project, new onset, exacerbation or recurrence of heart failure assessed by the New York Heart Association (NYHA) classification or angina pectoris; (4) renal event-doubling of serum creatinine (this is not considered as a renal event if the level is p2.0 mg per 100 ml), serum creatinine of X4.0 mg per 100 ml or end-stage renal disease (requiring dialysis or renal transplantation); (5) vascular event-new onset or exacerbation of dissecting aneurysm of aorta or arteriosclerotic peripheral arterial disease; and (6) other cardiovascular events-when the physician reported that his/her patient possibly had a cardiovascular event which did not meet the above criteria, the event evaluation committee assessed the occurrence individually.
In this sub-analysis, CKD was defined as creatinine clearance o60 ml min À1 , which was calculated by the Cockroft-Gault formulae 13 and/or proteinuria at baseline, whereas LVH was defined as a left ventricular posterior wall or interventricular septal thickness X12 mm on echocardiography or Sv1+Rv5 X35 mm on electrocardiography.
Statistical methods
The association between the achieved BP and the occurrence of cardiovascular events was analyzed in patients who made at least one follow-up visit without any cardiovascular events. The achieved BP was defined as the BP measured at the final study visit. In patients who experienced a cardiovascular event, the achieved BP was defined as that measured within 6 months before the event occurred. The achieved SBP and DBP were classified into five levels (SBP: o130, 130-139, 140-149, 150-159 and X160 mm Hg; DBP: o75, 75-79, 80-84, 85-89 and X90 mm Hg).
We calculated the crude incidence rates (per 1000 person-years) of cardiovascular events in the subsets of patients with DM, CKD or LVH. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by the multiple Cox proportional hazard model with adjustment for patient characteristics (sex, age, body mass index, treatment group, antihypertensive treatment before starting the CASE-J trial, smoking, drinking, DM, hyperlipidemia, severe hypertension, a history of cerebrovascular events, a history of ischemic heart disease, LVH and renal dysfunction) by setting a reference category at o130 mm Hg for SBP and at 75-79 mm Hg for DBP in the subset of patients without DM, CKD or LVH. The interaction between the status of complication and the achieved BP as a continuous variable was also assessed using the interaction term in the multiple Cox proportional hazard model. Statistical tests were two-sided and the level of significance was set at Pp0.05. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Demographic profile
A total of 4728 patients with essential hypertension were enrolled in the CASE-J trial. Among them, 4703 patients were evaluated for efficacy, comprising 2354 candesartan-treated patients and 2349 amlodipine-treated patients. The mean follow-up time was 3.2 years and 2.9% of patients were lost to follow-up. In this sub-analysis, 4553 patients (2278 in the candesartan group and 2275 in the amlodipine group) had at least one follow-up visit without any cardiovascular events. The baseline characteristics of the subjects are shown in Table 1 . The mean SBP/DBP at enrollment was 162.7/91.6 mm Hg and controlled to 136.2/77.5 mm Hg after 3 years. Since DM, LVH or renal dysfunction is one of the entry criteria, the proportions of other each baseline characteristic were higher compared with the general population in patients without complications.
Relationship between the achieved BP and the incidence of cardiovascular events The event number and crude incidence rate of each achieved BP level with or without any complication (DM, LVH or CKD) are shown in the first row of Table 2 . About 85% of patients in the CASE-J trial had DM, LVH or CKD at baseline. The crude incidence of cardiovascular events stratified by the achieved BP levels and the status of baseline risks are also shown in Table 2 . With regard to DM, the hazards of all achieved SBP levels in patients with DM were significantly higher compared with those of the achieved SBP o130 mm Hg in patients without DM (Figure 2a ).
Although the lower achieved SBP positively associated with the magnitude of risk reduction for both hypertensive patients with and without DM, the slope in patients without DM was steeper than that in patients with DM in SBP (interaction P¼0.019). The patients with SBP 130-139 mm Hg without DM achieved almost same risk as those with SBP o130 mm Hg (HR¼1.05, 95% CI¼0.56-1.97, P¼0.877), whereas the patients with DM still showed a higher risk of cardiovascular events, even in patients who achieved SBP o130 mm Hg (HR¼2.31, 95% CI¼1.24-4.33, P¼0.009). Figure 2b shows the increased risk of cardiovascular events at higher achieved DBP in parallel and there was no interaction between patients with and without DM in DBP (interaction P¼0.687). In hypertensive patients with CKD, the increased risk of cardiovascular events was associated with the higher SBP and DBP (Figure 4 ). Similar to DM, patients with CKD still showed a higher risk of cardiovascular events, even in patients who achieved SBP o130 mm Hg (HR¼2.86, 95% CI¼1.47-5.58, P¼0.002) and DBP o75 mm Hg (HR¼4.64, 95% CI¼1.99-10.80, Po0.001), compared with those without CKD. There was significant interaction between the status of CKD and of the achieved SBP and DBP.
DISCUSSION
This study verified that strict BP control leads to risk reduction of cardiovascular events in high-risk hypertensive patients with DM or CKD, and is the first to show that risk reduction was also observed in patients with LVH. Interestingly, the adjusted HR indicated that the risk of cardiovascular events increased gradually following a linear regression curve when SBP exceeded 130 mm Hg and DBP exceeded 80 mm Hg in hypertensive patients with these risk factors. In the group without complications, however, the adjusted HR for cardiovascular events increased similar to the report by Port et al., 14 with the threshold being 140-150/85 mm Hg.
In the Hypertension Optimal Treatment trial, the optimal target BP for prevention of cardiovascular events was analyzed in hypertensive patients with DM. This analysis revealed that the incidence of cardiovascular events was significantly lower in the group with the achieved DBP set at p80 mm Hg than those with the achieved DBP Achieved BP and prognosis in high-risk hypertension T Ogihara et al set at p85 and p90 mm Hg. 15 The results of some other studies in hypertensive patients with DM have also suggested that greater benefit is obtained by setting the target BP at a lower level. 16, 17 Therefore, the Joint National Committee (JNC) 7 5 and the European Society of Hypertension-European Society of Cardiology (ESH-ESC) Guidelines, 6 as well as the guideline of JSH 2004, 4 recommend o130/ 80 mm Hg as the target optimal BP level in hypertensive patients with DM. Our study showed the results consistent with these recommendation for hypertensive patients with DM. For hypertensive patients with CKD, a meta-analysis of 11 randomized controlled studies revealed that the incidence of end-stage renal failure and doubling of the serum creatinine were reduced by controlling SBP to 110-129 mm Hg in hypertensive patients with urine protein excretion 41.0 g day À1 . 18 Achieved BP and prognosis in high-risk hypertension T Ogihara et al essential hypertension, 19 both agents have been recommended for hypertensive patients with LVH. It was found that strict BP control is more important for reducing the left ventricular mass than the class of antihypertensive agent by comparison of six antihypertensive agents. 20 The most interesting point of this sub-analysis was that the risk of cardiovascular events in patients with LVH, who could achieve SBP o130 mm Hg or DBP 75-79 mm Hg, was reduced to the same level as in those without LVH, but not in patients with DM or CKD. This indicates that hypertensive patients with these complications should be treated with strict BP control, and it is important for DM and CKD patients to receive not only antihypertensive therapy but also sufficient treatment for DM and CKD. There are some limitations in this study. First, LVH was defined by criteria including electrocardiography, which is inferior in accuracy to echocardiography. Second, as this analysis was post hoc and patients were classified into several sub-groups, the population and the number of cardiovascular events in each group might not be enough to analyze the influence of achieved BP on these events. Third, we stratified by post-randomized variables; hence, this might introduce some bias whenever the association with outcome is confounded by more than just a baseline risk factor. Finally, as the CASE-J trial was not designed to determine the optimal BP levels in high-risk hypertensive patients, our results merely give an indication of the optimal BP levels when the patients received an antihypertensive treatment.
In conclusion, this sub-analysis of the CASE-J trial indicates that strict BP control leads to the risk reduction of cardiovascular events in hypertensive patients with DM, CKD or LVH. Further investigation in a large-scale clinical trial is needed to determine the optimal target BP for LVH patients.
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